Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
07/2003
07/24/2003WO2003059282A2 Human monoclonal antibodies against cd30
07/24/2003WO2003059269A2 Acridone inhibitors of impdh enzyme
07/24/2003WO2003045999A3 Human vanilloid receptor protein and polynucleotide sequence encoding same
07/24/2003WO2003045333A3 Treatment of hyperproliferative diseases using active vitamin d analogues
07/24/2003WO2003032918A3 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
07/24/2003WO2003032910A3 Carbinols for the treatment of neuropathic dysfunction
07/24/2003WO2003018612A3 Extracellular messengers
07/24/2003WO2003002091A3 Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
07/24/2003WO2002086107A3 A method for differentiating stem cells into insulin-producing cells
07/24/2003US20030139452 Pyrazole-derived kinase inhibitors and uses thereof
07/24/2003US20030139417 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof
07/24/2003US20030139413 Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical composition containing them
07/24/2003US20030139407 Efficient synthesis of 5-heteroatom-containing -pyrazoles
07/24/2003US20030139384 Transdermal supplying testosterone
07/24/2003US20030139347 Pralmorelin-containing nasal drop preparations
07/24/2003US20030138839 Polypeptide comprising ubiquitination regulating domain; antiproliferative agents; neuroprotectants; cancer diagnosis
07/24/2003US20030138803 Identification and use of molecules implicated in pain
07/24/2003US20030138772 Polymerase chain reactions to screen and isolate parvovirus DNA obtained from tissue and/or cells without coinfection by helper viruses; gene therapy
07/24/2003CA2680946A1 Pim-3 kinase as a target for type 2 diabetes mellitus
07/24/2003CA2473908A1 Compounds for blocking androgen receptors
07/24/2003CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
07/24/2003CA2472204A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
07/24/2003CA2471702A1 Human monoclonal antibodies against cd30
07/24/2003CA2471483A1 Polytartrate composition
07/24/2003CA2470359A1 Assay for the detection of factors that modulate the expression of ingap
07/23/2003EP1329511A1 Polypeptide having phospholipase a2 actiivty
07/23/2003EP1329508A1 Novel g protein-coupled receptor protein and dna thereof
07/23/2003EP1329458A2 Peptides that lower blood glucose levels
07/23/2003EP1328653A2 Highly expressible genes
07/23/2003EP1328624A2 B7-like molecules and uses thereof
07/23/2003EP1328619A1 Human tuberoinfundibular peptide of 39 residues
07/23/2003EP1328545A1 Human gene critical to fertility
07/23/2003EP1328522A2 Estrogen receptor modulators
07/23/2003EP1328276A1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
07/23/2003EP1328265A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
07/23/2003EP1328259A2 Transdermal therapeutic systems comprising photosensitive active substances
07/23/2003EP1328252A2 Transdermal pharmaceutical delivery composition
07/23/2003EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
07/23/2003EP1148876A4 Calcilytic compounds
07/23/2003CN1431998A Growth hormone secretagogues
07/23/2003CN1431904A Protease inhitors
07/23/2003CN1431902A Therapeutic combinations of antihypertensive and antiangiogenic agents
07/23/2003CN1431899A Pharmaceutical combination of bicalutamide and tamoxifen for providing anti-androgenic effect and anti-oestrogenic effect
07/22/2003US6596885 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions
07/22/2003US6596867 Bone disorders
07/22/2003US6596753 Compounds of the indolecarboxylic family and use thereof
07/22/2003US6596746 Cyclic protein tyrosine kinase inhibitors
07/22/2003US6596738 Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I):
07/22/2003US6596730 Phenyl urea and phenyl thiourea derivatives
07/22/2003CA2294422C Tartrate salt of a substituted dipeptide
07/22/2003CA2275166C Novel benzopyran derivatives
07/22/2003CA2243274C Male contraceptive implant
07/17/2003WO2003057862A2 Transdifferentiation of pancreatic acinar cells
07/17/2003WO2003057856A2 Dominant negative proteins and methods thereof
07/17/2003WO2003057725A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
07/17/2003WO2003057264A1 Feminine care products for the delivery of therapeutic substances
07/17/2003WO2003057252A1 Human mast cell-expressed membrane proteins
07/17/2003WO2003057225A2 Phosphate transport inhibitors
07/17/2003WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
07/17/2003WO2003057196A1 Drug mixture with enhanced dissolution rate
07/17/2003WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
07/17/2003WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols
07/17/2003WO2002072626A3 Novel form of the phgpx protein as a diagnostic marker for male infertility
07/17/2003WO2002055693A3 Method for inhibiting the expression of a target gene
07/17/2003WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses
07/17/2003WO2002011713A3 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
07/17/2003US20030134899 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
07/17/2003US20030134898 N-Acetylsulfamic acid derivatives
07/17/2003US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc.
07/17/2003US20030134886 Pharmaceutically active compounds
07/17/2003US20030134879 Substituted with a thio, sulfoxy or sulfonyl group
07/17/2003US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus
07/17/2003US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease
07/17/2003US20030134834 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain
07/17/2003US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate,
07/17/2003US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as
07/17/2003US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid
07/17/2003US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides
07/17/2003US20030133992 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
07/17/2003US20030133980 Biocompatible polymer blends and uses thereof
07/17/2003US20030133964 Polymeric delivery formulations of leuprolide with improved efficacy
07/17/2003US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen.
07/17/2003CA2472585A1 Drug mixture with enhanced dissolution rate
07/17/2003CA2472111A1 Human mast cell-expressed membrane proteins
07/17/2003CA2472049A1 Dominant negative proteins and methods thereof
07/17/2003CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
07/17/2003CA2469052A1 Transdifferentiation of pancreatic acinar cells
07/17/2003CA2467829A1 Feminine care products for the delivery of therapeutic substances
07/16/2003EP1326894A2 Novel tumor-associated marker
07/16/2003EP1326868A1 Morphinoid derivatives as delta-opioid agonists and antagonists
07/16/2003EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
07/16/2003EP1326859A1 Quinazoline derivatives with anti-tumour activity
07/16/2003EP1326858A2 Piperidine compounds as anti-allergic
07/16/2003EP1326853A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
07/16/2003EP1326851A1 Substituted dipeptides as growth hormone secretagogues
07/16/2003EP1326825A2 Compounds and compositions for delivering active agents
07/16/2003EP1326631A1 Methods for treating endocrine disorders
07/16/2003EP1326630A2 Use of glp-1 and glp-2 peptides
07/16/2003EP1326618A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases
07/16/2003EP1326606A2 Ep4 receptor inhibitors to treat rheumatoid arthritis
1 ... 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 ... 290